Captrust Financial Advisors Mi Nk Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 35,729 shares of INKT stock, worth $27,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,729
Previous 54,291
34.19%
Holding current value
$27,868
Previous $49,000
32.65%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
901KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$182,6610.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$129,9990.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$99,7150.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$75,1500.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$68,0120.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $26.3M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...